FMP
Harmony Biosciences Holdings, Inc.
HRMY
NASDAQ
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
32.72 USD
0 (0%)
Build Up Free Cash Flow
Year
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Revenue
3.22B
3.08B
3.34B
3.8B
4.13B
4.41B
4.7B
5.02B
5.35B
5.71B
Operating Cash Flow
212.7M
245M
369.7M
252.2M
256.3M
339.29M
361.95M
386.12M
411.91M
439.41M
Cap Ex
-167.6M
-104.5M
-94M
-150.3M
-184.9M
-174.99M
-186.68M
-199.14M
-212.44M
-226.63M
Free Cash Flow
45.1M
140.5M
275.7M
101.9M
71.4M
164.3M
175.27M
186.98M
199.46M
212.79M
Wacc
5.59
5.59
5.59
5.59
5.59
Pv Lfcf
155.6M
157.21M
158.83M
160.47M
162.12M
Sum Pv Lfcf
794.24M
